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Natural antisense transcripts (asRNAs) transcribed from eukaryotic genes are primarily long transcripts that do 
not code for proteins. Transcriptome analyses have revealed that asRNAs exhibit diverse functional roles in the 
regulation of gene expression. In the case of inducible genes, asRNAs epigenetically affect their expression or 
post-transcriptionally affect stability and translatability of their mRNAs. Many low-copy-number asRNAs 
regulate the expression levels of mRNAs through cis-controlling elements in the mRNA in concert with 
trans-acting factors, such as RNA-binding proteins and microRNAs. Recently, a competitive endogenous RNA 
(ceRNA) hypothesis was postulated as the basis of a functional network, comprising mRNAs, asRNAs, and 
microRNAs. This network finely tunes mRNA expression by common microRNA-responsive elements being 
present among mRNAs and asRNAs, permitting the redirection of microRNAs between the two. Examples of the 
ceRNA-mediated cross-regulation of mRNA expression are observed in the phosphatase and tensin homolog 
mRNA network and the interferon-alpha1 mRNA network. In such regulatory RNA networks, an mRNA, its 
corresponding asRNAs (high specificity), microRNAs (low specificity), and RNA-binding proteins mutually 
interact. Both asRNAs and microRNAs are involved in the pathogenesis or pathophysiology of various diseases, 
such as cancer, inflammation, and infection. Simple disruption of an asRNA or a microRNA can often show 
off-target effects due to complicated interactions inside and outside the regulatory RNA networks. Therefore, 
drugs that target asRNAs should be developed to minimize off-target effects and to target interactions that are 
dysregulated in disease. 
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Natural antisense RNA transcripts as a therapeutic target 
Natural antisense transcripts (asRNAs) are transcribed 
from many eukaryotic genes, as well as from pseudogenes [1]. 
An asRNA has the same sequence as that of the 
complementary (antisense) strand of a gene, whereas the 
mRNA has the same sequence as that of the sense strand. 
Therefore, most asRNAs do not encode proteins, are more 
than 200 nucleotides in length, and are distinct from small 
non-coding RNAs such as microRNAs. Most asRNAs are 
thus classified as long non-coding RNAs (lncRNAs) [2]. 
Transcriptome analyses of mammalian genomes have 
demonstrated that asRNAs are frequently transcribed, 
indicating a role for asRNAs in gene regulation [3, 4]. 
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However, to date, only a few asRNAs have been functionally 
validated. 
Accumulated data have revealed that asRNAs have a 
broad array of functions in the regulation of gene expression 
by a variety of mechanisms. Both asRNAs and lncRNAs can 
alter gene expression at almost all steps of gene expression, 
from transcription to translation [1, 5]. In the expression of 
inducible genes in response to various stimuli, asRNAs 
epigenetically enhance the expression of these genes or 
post-transcriptionally affect stability and translatability of 
mRNA. asRNAs are assumed to regulate the expression of 
mRNAs through their cis-controlling elements (usually 
single-stranded regions) in concert with trans-acting factors, 
such as RNA-binding proteins and microRNAs [1]. Indeed, 
the interferon (IFN)-alpha1 asRNA modulates stability and 
thereby translatability of IFN-alpha1 mRNA at a 
post-transcriptional level [6]. 
The expression levels of asRNAs are generally much 
lower than those of mRNAs [1]. Despite this, asRNAs have 
distinct and diverse functions, and the mechanism of 
asRNA-mediated gene regulation differs for each gene [1]. 
Genome-wide expression analyses of nine different tissues 
from humans, mice, and rats show that asRNA expression is 
conserved [7]. Additionally, despite low levels of asRNAs 
expression, conservation of asRNA nucleotide sequences and 
secondary structures is also observed among species [1].  
In various diseases, such as inflammatory or infectious 
diseases, neurodegenerative disorders, and cancer, many 
asRNAs are over-expressed, implying that asRNAs may be 
involved in the pathogenesis or pathophysiology of these 
diseases [8]. Initial approaches to target and ‘knockdown’ 
asRNAs involved the use of short interfering RNAs 
(siRNAs), which resulted in destabilization of cognate 
mRNAs, and a decrease in their levels. This silencing 
method successfully decreased levels of the mRNAs 
encoding endothelial nitric oxide synthase (eNOS) [9] and 
beta-site amyloid precursor protein-cleaving enzyme 1 
(BACE1), which is involved in the development of 
Alzheimer’s disease [10].  
Unexpectedly, disruption of asRNAs also led to increases 
in the levels of some mRNAs, including those for 
brain-derived neurotrophic factor (BDNF), glial-derived 
neurotrophic factor (GDNF), and ephrin receptor B2 [11]. 
Therefore, the asRNA knockdown approach results in both 
concordant mRNA regulation (mRNA decrease) and 
discordant mRNA regulation (mRNA increase) [12]. These 
findings suggest that the asRNA-mediated mechanism of 
mRNA regulation is much more complicated than previously 
predicted.  
Here, we focus on the networks among regulatory RNAs 
(asRNAs and microRNAs) that regulate mRNA expression, 
and we provide an overview of interactions in the networks 
that can potentially be exploited as drug targets. 
Involvement of asRNAs in disease 
asRNAs function to regulate mRNA levels as part of the 
overall mechanism that controls gene expression. However, 
dysregulated gene expression frequently results in disease 
and altered asRNA expression has been reported in many 
diseases, such as cancer, Alzheimer’s disease, Parkinson’s 
disease, spinocerebellar ataxia, Huntington’s disease, and 
autoimmune diseases [8, 13, 14]. Here, we describe several 
examples of asRNA-mediated post-transcriptional 
mechanisms involved with disease.  
Cancer 
Tumor suppressor genes, such as P53 and the phosphatase 
and tensin homolog (PTEN), are post-transcriptionally 
regulated by asRNAs [15, 16]. PTEN, 
phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase, 
negatively regulates the phosphatidylinositol-4,5- 
bisphosphate 3-kinase (PI3K)-Akt pathway, and its gene is 
mutated at a high frequency in a large number of cancers [17]. 
Furthermore, a subtle decrease in Pten gene expression is 
sufficient to promote cancer susceptibility in mice that 
express 80% normal levels of Pten mRNA [18]. PTEN 
expression is regulated by the action of a PTEN pseudogene 
(PTENpg1) at a post-transcriptional level [16]. The sense 
transcript transcribed from this pseudogene is an lncRNA 
(PTENpg1 lncRNA), which shares common 
microRNA-responsive elements (MREs, to which 
microRNAs may bind) with PTEN mRNA. Therefore, 
PTENpg1 lncRNA sequesters numerous PTEN-targeting 
microRNAs by acting as an endogenous microRNA 
‘sponge’. This competition with PTEN mRNA for 
microRNA binding, results in upregulation of PTEN mRNA. 
This type of transcript (PTENpg1 lncRNA) is designated as a 
competitive endogenous RNA (ceRNA) [19].  
Two asRNAs isoforms (alpha and beta) are transcribed 
from the PTENpg1 locus [16]. PTENpg1 asRNA-alpha 
epigenetically modulates PTEN transcription. In contrast, 
PTENpg1 asRNA-beta stabilizes PTENpg1 lncRNA through 
an RNA–RNA interaction, thereby increasing stability of 
PTENpg1 lncRNA and maintaining its microRNA sponge 
activity [16]. When PTENpg1 asRNA-beta is depleted, 
microRNAs are released from the PTENpg1 lncRNA and 
bind to PTEN mRNA, leading to a decrease in PTEN protein 
levels. These data show that the network mediated by the 
sense and antisense transcripts from the PTENpg1 
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pseudogene finely regulates PTEN mRNA degradation and 
translation.  
Inflammation and infection 
During infection-provoked inflammation, mRNAs are 
rapidly transcribed from inducible genes. Among them, early 
response genes [20], such as inducible nitric oxide synthase 
(iNOS), proinflammatory cytokines [e.g., tumor necrosis 
factor-alpha (TNF-alpha)], and chemokines, are intimately 
involved in the pathophysiology of inflammation and 
infection. In the presence of interleukin 1beta, iNOS asRNA 
interacts with and stabilizes iNOS mRNA [21]. 
Single-stranded sense oligodeoxyribonucleotides 
corresponding to the iNOS mRNA sequence decrease iNOS 
mRNA levels by interfering with mRNA-asRNA interactions 
[21]. This method is referred to as natural antisense 
transcript-targeted regulation (NATRE) technology [22]. In 
contrast, when sense oligonucleotides corresponding to other 
mRNAs that are involved in inflammation (e.g., mRNAs 
encoding TNF-alpha, nuclear factor-kappaB p65 subunit, and 
several chemokines) were introduced into hepatocytes, their 
mRNA levels increased (discordant regulation) [23, 24]. 
Following viral infection, IFN-alpha proteins induce the 
expression of IFN-stimulated genes, leading to antiviral 
activity. IFN-alpha proteins, which are classified as type I 
IFNs, consist of 13 functional subtypes that show high 
homology to IFN-alpha1 (i.e., the IFN-alpha multigene 
family) [25]. Infection of human Namalwa lymphocytes with 
Sendai virus or infection of guinea pig fibroblasts with 
influenza virus elevated the expression of IFN-alpha1 
asRNA [6]. IFN-alpha1 asRNA stabilizes IFN-alpha1 mRNA 
by interacting with a bulged stem-loop (BSL) region formed 
by the IFN-alpha1 mRNA [6]. The IFN-alpha1 asRNA may 
mask the microRNA-1270 (miR-1270)-binding site in the 
BSL region of the IFN-alpha1 mRNA and prevent 
microRNA-induced destabilization of the target mRNA, 
leading to IFN-alpha1 mRNA stabilization. Furthermore, 
antisense oligoribonucleotides (i.e., asRNA mimics of 
IFN-alpha1 asRNA) elevated IFN-alpha1 mRNA expression 
[6]. 
Regulatory RNA networks 
mRNA–asRNA interactions 
asRNAs involved in post-transcriptional mechanisms are 
hypothesized to be potential drug targets, with disruption of 
the interaction between asRNAs and mRNAs a promising 
strategy. Both sense oligodeoxyribonucleotides [11, 21–24] and 
antisense oligoribonucleotides (asRNA mimics) [6] have been 
successfully used to interfere with this interaction. The copy 
number of an asRNA is generally lower than that of an 
mRNA, although asRNAs have high specificity to their 
cognate mRNAs. A recycling model for mRNA–asRNA 
interactions has been postulated [26]. When an asRNA 
interacts with an mRNA by hybridizing to loops in secondary 
structures, it recruits RNA-binding protein(s) and then 
detaches itself from the mRNA to interact with another 
mRNA. This model may explain how a low-copy number 
asRNA affects the functions of its mRNA by recycling of the 
asRNA molecule. 
The lncRNA and mRNAs in the PTEN gene-centered ceRNA 
network 
A high-copy number microRNA targets an mRNA 
through its seed sequence at relatively low specificity and 
may be another pivotal player in the regulation of mRNA 
expression. As mentioned above, PTENpg1 asRNA-beta 
stabilizes PTENpg1 lncRNA, which indirectly regulates the 
levels of PTEN mRNA as a ceRNA. Any transcript that is 
non-coding and that shares common MREs (i.e., a lncRNA 
or asRNA) may be a ceRNA [19]. ceRNA crosstalk has been 
discovered in many species and is assumed to be involved in 
mRNA degradation [19].  
Another type of ceRNA is represented by several 
protein-coding transcripts (e.g., VCAN, VAPA, and ZEB2 
mRNAs) that share microRNAs with the PTEN mRNA 
[27–29]. These mRNAs up-regulate the PTEN mRNA through 
MREs to modulate PTEN protein levels in a 
microRNA-dependent, protein-coding-independent fashion. 
Because the expression levels of these mRNAs correlate with 
various types of human cancer, the PTEN gene-centered 
ceRNA network may contribute to PTEN function and 
tumorigenesis [29].  
asRNAs and mRNAs in the IFN-alpha1 gene-centered ceRNA 
network 
Recent studies have reported asRNAs that share several 
MREs with their corresponding mRNAs. Kimura et al. 
investigated a possibility that IFN-alpha1 asRNA may also 
function as a ceRNA, in addition to competing with 
miR-1270 for IFN-alpha1 mRNA [25]. The authors found that 
IFN-alpha1 asRNA harbors multiple MREs for miR-1270 
and that IFN-alpha1 asRNA forms a ceRNA network 
specifically with both mRNAs and asRNAs of the IFN-alpha 
family genes to antagonize miR-1270, thereby positively 
affecting IFN-alpha1 mRNA levels. These results suggest 
that IFN-alpha1 asRNA, together with asRNAs (alpha7, 8, 
10, and 14) and mRNAs (alpha8, 10, 14, and 17) of specific 
IFN-alpha subtypes, act as competing molecules in the 
ceRNA network [25]. The IFN-alpha1 gene-centered ceRNA 
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network is newly identified and forms a large regulatory 
network among many IFN-alpha family genes. 
Furthermore, introduction of antimiR-1270 (an 
oligoribonucleotide complementary to the seed sequence of 
miR-1270) resulted in specific de-repression of other five 
mRNAs, indicating that these mRNAs also function in the 
ceRNA network [25]. Among the five mRNAs, the cell 
cycle-associated protein 1 (CAPRIN1) mRNA is included, 
and CAPRIN1 can modulate signaling events that are 
necessary for translation of IFN-stimulated genes [30–32]. The 
use of antimiR led to the discovery that CAPRIN1 mRNA 
modulates antiviral immunity by finely tuning the IFN-alpha 
response in a protein-coding-independent fashion [25]. 
The coordinated regulatory networks for IFN-alpha1 
mRNA expression suggest a vital function for the innate 
immune system to precisely maintain physiological 
expression levels of IFN-alpha proteins [25]. Indeed, an 
antisense oligoribonucleotide that stabilizes IFN-alpha1 
mRNA caused a reduction in human influenza A virus titers 
in the respiratory tract of infected guinea pigs (Kimura et al., 
unpublished results). The IFN-alpha1 gene-centered ceRNA 
network may be critical for the innate immune responses 
against viral infection. 
RNA–RNA interactions in a regulatory RNA network 
Several parameters may affect the interactions among 
mRNAs, asRNAs, and microRNAs in a regulatory RNA 
network. First, the stoichiometry of RNA molecules and 
MREs should be considered. Examining the stoichiometry of 
RNA molecules in a ceRNA network raises several 
questions, such as how a low-copy-number asRNA with high 
specificity interacts with high-copy-number microRNAs with 
low specificity [29, 33]. These questions will be solved as the 
details of ceRNA networks are clarified. 
Second, structures of mRNAs and asRNAs, as well as 
conformation of their hybrids, should be considered. 
Single-stranded regions (loops or bulges) in the secondary 
structures of mRNAs are assumed to be sites of interaction 
with asRNAs and microRNAs [6, 21]. Exposure of the 
single-stranded regions in an mRNA may trigger binding to 
its partner RNA. This may induce changes in duplex 
conformation and to local structures, which may enhance or 
suppress binding of RNA-binding proteins [1, 34]. 
Additionally, various drugs may alter the stem-loop 
structures and duplex conformation of RNA, for example by 
intercalating in RNA duplexes or binding to RNA [1]. 
Because new approaches to analyze in vivo RNA structures 
have recently been developed [35, 36], clarification of detailed 
RNA structures will be possible in the future.  
Third, accessibility and affinity of an RNA molecule for 
its partners should be considered [1]. A recent study clarified 
the function of N6-methyladenosine (m6A), which is the 
prevalent internal modification present in mRNAs of all 
higher eukaryotes [37]. The m6A modification regulates 
degradation of mRNA and lncRNA through RNA-binding 
proteins (YTHDF2 proteins) that recognize and bind to m6A 
[37]. Because asRNAs are classified as lncRNAs, asRNAs 
might be m6A modified, and the modification might regulate 
stability of the asRNA. Interestingly, m6A modification also 
controls the RNA structure-dependent accessibility of 
RNA-binding proteins to affect mRNA–protein interactions 
[38]. When m6A-modified asRNAs interact with mRNAs, the 
asRNAs may indirectly regulate mRNA stability and its 
accessibility to RNA-binding proteins.  
Finally, small polypeptides encoded by lncRNAs might 
also be functional [39]. Recent reports suggest a possibility 
that small polypeptides (20–100 amino acids) translated from 
short open reading frames (ORFs) of lncRNAs have 
biological activities. Although such ORFs in asRNAs and 
lncRNAs are generally ignored in gene annotation 
algorithms, the small polypeptides translated from these 
ORFs might affect the interactions in the regulatory RNA 
network, leading to changes of gene expression. 
Detailed knowledge of the various interactions within 
these regulatory networks remains limited. Future studies 
will help pave the way for the development of new drugs that 
target critical interactions in these networks. 
Drugs that target asRNAs in regulatory RNA networks 
RNA has long been a drug target, although drug–RNA 
interactions have not been well studied. A drug that targets 
an asRNA is expected to affect multiple interactions in a 
regulatory RNA network, including RNA–RNA interactions. 
The mechanism of asRNA-mediated gene regulation differs 
among genes, and sometimes involves a ceRNA network. 
Therefore, the drug should be specific in its targeting of 
asRNA with minimal off-target effects. Several drugs have 
been designed to regulate the functions of asRNAs based on 
their mechanisms of action, in a similar manner to drugs that 
target lncRNAs [13].  
(1) Degradation of asRNAs. In this strategy, siRNA is 
used as a potential drug to disrupt a single asRNA molecule, 
resulting in impairment of its functions [9, 10]. However, if the 
asRNA functions as a ceRNA and its MREs are shared by 
other asRNAs or mRNAs, off-target effects may occur. 
Therefore, silencing of an asRNA alone is sometimes 
insufficient to normalize dysregulated gene expression in 
disease. 
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 (2) Functional block of asRNAs. Interaction sites for 
binding partners (mRNAs, microRNAs, or RNA-binding 
proteins) are blocked by sense oligonucleotides, asRNA 
mimics (oligoribonucleotides), or antimiRs (oligonucleotides 
complementary to microRNA seed regions) [6, 11, 21, 22, 25]. 
These oligonucleotides have the potential to be used for a 
therapeutic purpose. Some of these oligonucleotides may 
also possess activity to degrade asRNA to affect stability and 
translatability of mRNA. Alternatively, when an asRNA 
harbors multiple MREs, asRNA mimics may sequester 
microRNAs. Therefore, these oligonucleotides have potential 
to be nucleic acid drugs that can modulate RNA interactions 
in disease.  
(3) Structure disruption. A drug may bind to a specific 
structure in an asRNA to inhibit binding with partners. This 
type of drug is usually associated with the loss of asRNA 
function [1]. Previous studies have reported classical 
low-molecular-weight drugs that specifically bind to RNA to 
disrupt structure and block function. A famous example is 
aminoglycoside antibiotics, which bind to the 
aminoacyl-transfer RNA decoding site (A site) on the 16S 
ribosomal RNA to interfere with translation in bacteria [40]. 
However, only a few other drugs that specifically recognize 
RNA structures are known. For example, acetylpromazine, a 
psychotropic drug, recognizes and binds to the specific 
structure of transactivation-responsive (TAR) RNA, to which 
the transactivating regulatory (Tat) protein of human 
immunodeficiency virus type I (HIV-1) binds [41]. RNA 
aptamers, which bind to asRNA (or RNA-binding proteins) 
in a structure-specific, but sequence-independent manner, 
may also function as drugs to disrupt structures.  
Many constituents of herbal medicines, which have low 
molecular weights (less than 1,000), destabilize iNOS 
mRNA, indicating that they might interfere with the iNOS 
mRNA–asRNA interaction [1]. Indeed, epigallocatechin 
gallate and apigenin, both of which are flavonoids in herbal 
medicines, bind to RNA with high affinity [42, 43], suggesting 
the possibility that flavonoids interfere with mRNA–asRNA 
interactions. Detailed studies on such drugs are required to 
elucidate how the drug–RNA interactions affect various 
interactions in a regulatory RNA network.  
Perspectives 
Here, we provide an overview of regulatory RNA 
networks. Within a network, regulatory RNAs (asRNAs, 
microRNAs, and other lncRNAs), as well as RNA-binding 
proteins, mutually interact to finely tune mRNA expression. 
In this sense, a regulatory RNA network resembles the solar 
system, which harbors the sun (mRNA), planets (asRNAs), 
and asteroids (microRNAs and RNA-binding proteins) 
(Figure 1). MicroRNAs and RNA-binding proteins 
cross-interact with other networks, and an asRNA or mRNA 
may act as a ceRNA to sequester microRNAs from inside 
and outside the network. Therefore, the transcriptome in the 
cell, which consists of many networks, can appear as a 
‘microcosmos’. Understanding this ‘RNA microcosmos’ will 
lead to the development of new drugs. 
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Figure 1. The RNA microcosmos in the cell. A model of regulatory 
RNA networks in the cell is schematically depicted. Each network 
(shown by a circle) consists of an mRNA, an antisense transcript 
(asRNA), many microRNAs (miRs), and various RNA-binding 
proteins (RBPs). The asRNAs, miRs, and RBPs affect the 
expression of mRNAs (arrows). miRs and RBPs may enter another 
regulatory RNA network and regulate the expression of another 
mRNA (broken double-headed arrows). As ceRNAs, an asRNA (red) 
or mRNA (blue) may sequester miRs inside and outside the network 
(bold stopped lines), resulting in the up-regulation of mRNA (i.e., 
asRNA2 versus mRNA2, and asRNA2 versus mRNA3). An mRNA 
may also show the ceRNA effect on another mRNA (i.e., mRNA3 
versus mRNA1), such as in the PTEN gene- and IFN-alpha1 
gene-centered networks. Therefore, a regulatory RNA network 
cross-interacts with other networks to affect mRNA expression via 
miRs, RBPs, and ceRNAs. All the regulatory RNA networks in the 
cell form a transcriptome, the ‘RNA microcosmos’. 
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